LAMTOR5 and breast carcinoma: To determine whether HBXIP participates in anoikis in breast cancer cells, we established stable overexpression or knockdown of HBXIP via the ectopic expression of HBXIP cDNA or HBXIP shRNA using lentiviral technology.